Lantern Pharma Inc. (NASDAQ: LTRN) announced a strategic collaboration with French biotech company Oregon Therapeutics to enhance the development of XCE853, a first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate. The partnership, utilizing Lantern Pharma’s proprietary RADR AI platform, aims to identify biomarkers and gene signatures that will guide XCE853’s clinical application in treating various […]
Lantern Pharma Inc. (NASDAQ: LTRN), a trailblazer in artificial intelligence (AI) and machine learning (ML) for targeted cancer therapies, has received clearance from the United States Food and Drug Administration (FDA) for its investigational new drug (IND) application concerning LP-284. The cutting-edge drug is being developed for relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle […]
Lantern Pharma said that the US Food and Drug Administration (FDA) has authorized it to move ahead with its Harmonic phase 2 clinical trial of LP-300, its investigational new drug in never smokers with non-small cell lung cancer (NSCLC). Harmonic will involve 90 patients in a multi-center, two arm, open-label, and randomized study for assessing […]
Lantern Pharma has secured orphan drug designation for its small molecule drug candidate LP-184 from the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer. According to the Texas-based clinical stage biopharma company, LP-184 is a next generation alkylating agent that selectively damages DNA in cancer cells that over-express certain biomarkers or […]
